Ipsen SA and Biomunex Pharmaceuticals SAS have signed an exclusive global licensing agreement for BMX-502, a preclinical novel T-cell engager with potential for solid tumors. BMX-502 is a bispecific antibody that engages and activates mucosal-associated invariant T (MAIT) cells and targets the GPC3 tumor antigen, to kill cancer cells.
Sarepta Therapeutics Inc. has signed a licensing and collaboration agreement with Arrowhead Pharmaceuticals Inc. to obtain exclusive global rights to multiple clinical, preclinical and discovery-stage programs for rare genetic diseases of the muscle, central nervous system (CNS) and the lungs. The deal includes ARO-DUX4, ARO-DM1, ARO-MMP7 and ARO-ATXN2.
Telix Pharmaceuticals Ltd. is expanding its theranostic pipeline with new assets targeting fibroblast activation protein (FAP). The company has entered into asset purchase and exclusive worldwide in-license agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine (diagnostic) radiopharmaceutical candidates developed at Johannes Gutenberg-Universität Mainz.
Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to license the therapy for further development and commercialization, resulting in a milestone payment to Quell of $10 million.
Artbio Inc. and 3B Pharmaceuticals GmbH have signed a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide α-radioligand therapy for the treatment of solid tumors.
Bayer AG has entered into an exclusive licensing agreement with Dewpoint Therapeutics Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients characterized by specific mutations.
Siga Technologies Inc. has entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (MAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox.
Cureverse Inc. and Angelini Pharma SpA signed a potential $360 million deal for CV-01, an oral small-molecule candidate for Alzheimer’s disease and neurological disorders like epilepsy. As a novel candidate, CV-01 suppresses neuroinflammatory reactions through the Kelch-like ECH-associated protein 1 and nuclear factor erythroid 2-related factor signaling pathway.
Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.
Ligachem Bioscience Inc., of Daejeon, South Korea, and Osaka, Japan-based Ono Pharmaceutical Co. Ltd. agreed to two antibody-drug conjugate (ADC) deals that could reach $700 million (₩943.5 billion) combined.
RSS
